Colorectal Cancer Treatments and Studies

A Tale of Two Cell Lines: Characterization of differential efficacy of small molecule drugs cediranib and NU-7441 on primary vs. metastatic colorectal cancer

This study compares the drug response and gene expression of two colorectal cancer cell lines, SW480 and SW620, to identify biomarkers for targeted therapies.

Reprogramming of Cellular Plasticity via ETS and MYC Core-regulatory Circuits During Response to MAPK Inhibition in BRAF-mutant Colorectal Cancer

This study shows BET + MAPK inhibitors improve efficacy against BRAFV600E CRC by inducing epigenetic reprogramming and cellular plasticity through enhancer dynamics disruption.

Single-cell Transcriptome Profiling of Post-treatment and Treatment-naive Colorectal Cancer: Insights into Putative Mechanisms of Chemoresistance

This study uses scRNA-seq to compare treatment-naive and post-treatment colorectal cancer samples, identifying markers and cell types associated with chemoresistance and response.

Targeting Colorectal Cancer Liver Metastasis Through Repurposing Metabolic and Immune Inhibitors : A Theoretical Study

This paper uses a Boolean Network model to evaluate metabolic and immune inhibitors for colorectal cancer liver metastasis, identifying effective drug combinations and potential improvements in treatment.

Cetuximab increases LGR5 expression and augments LGR5-targeting antibody-drug conjugate efficacy in patient-derived colorectal cancer models

This study shows cetuximab increases LGR5 expression and improves the efficacy of LGR5-targeting ADCs in colorectal cancer models.

Artificial intelligence for precision oncology: AI-HOPE-MAPK uncovers clinically actionable MAPK alterations in colorectal cancer

AI-HOPE-MAPK identifies age- and ancestry-specific MAPK pathway alterations in colorectal cancer, revealing clinically relevant mutation patterns and survival differences.

Precision Oncology Insights into WNT Pathway Alterations in FOLFOX-Treated Early-Onset Colorectal Cancer in High-Risk Populations

This study examines WNT pathway alterations in early-onset colorectal cancer across different populations and treatment groups, finding ancestry-specific effects of FOLFOX chemotherapy on mutation frequencies and survival outcomes.

Precision Oncology Through Dialogue: AI-HOPE-RTK-RAS Integrates Clinical and Genomic Insights into RTK-RAS Alterations in Colorectal Cancer

AI-HOPE-RTK-RAS enables dialogue-driven analysis of RTK-RAS alterations in CRC, revealing novel associations and ancestry-specific patterns in mutation prevalence and prognosis.

Modelling oxaliplatin resistance in colorectal cancer reveals a SERPINE1-based gene signature (RESIST-M) and therapeutic strategies for pro-metastatic CMS4 subtype

This paper identifies a SERPINE1-based gene signature (RESIST-M) that predicts oxaliplatin resistance and metastasis in colorectal cancer and proposes therapeutic strategies targeting this pathway.

LSD1 inhibition attenuates targeted therapy-induced lineage plasticity in BRAFV600E colorectal cancer

This study shows that LSD1 inhibition reduces lineage plasticity caused by BRAF and EGFR inhibitors in BRAFV600E colorectal cancer.

Integrative ensemble modelling of cetuximab sensitivity in colorectal cancer PDXs

The paper trains an ensemble classifier to predict cetuximab sensitivity in colorectal cancer PDXs using multi-omic data, achieving high accuracy and demonstrating its utility for therapeutic biomarker development.

Enhancing efficacy of the MEK inhibitor trametinib with paclitaxel in KRAS-mutated colorectal cancer

This study identifies paclitaxel as a synergistic partner for trametinib in KRAS-mutated colorectal cancer, showing enhanced anti-tumor effects in vitro and in vivo.

Gene interaction perturbation network deciphers a high-resolution taxonomy in colorectal cancer

The paper introduces a gene interaction perturbation network approach to classify colorectal cancer into six subtypes with distinct molecular and clinical features.

Consensus molecular subtyping of colorectal cancers is influenced by goblet cell content

This study shows that goblet cell content influences CMS3 subtype classification in colorectal cancer using machine learning.

Pharmacogenomics, biomarker network and allele frequencies in colorectal cancer

This paper reviews pharmacogenomics biomarkers and genomic alterations in colorectal cancer to improve precision medicine strategies, with a focus on Latin America.